Amylyx Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
12 October 2022 - 7:01AM
Business Wire
Amylyx Pharmaceuticals, Inc. (“Amylyx”) today announced the
closing of its previously announced upsized underwritten public
offering of 7,697,812 shares of its common stock at a public
offering price of $32.00 per share, which includes the exercise in
full by the underwriters of their option to purchase up to an
additional 1,004,062 shares of common stock in the offering. The
gross proceeds to Amylyx from the offering were $246.3 million,
before deducting underwriting discounts and commissions and
estimated offering expenses.
Goldman Sachs & Co. LLC, BofA Securities, SVB Securities,
and Evercore ISI acted as joint book-running managers for the
offering. H.C. Wainwright & Co. acted as lead manager for the
offering.
Registration statements on Form S-1 relating to these securities
became effective on October 6, 2022. The offering was made only by
means of a prospectus. Copies of the final prospectus relating to
the offering may be obtained from: Goldman Sachs & Co. LLC, at
Prospectus Department, 200 West Street, New York, New York 10282,
by telephone at 1-866-471-2526 or by e-mail at
prospectus-ny@ny.email.gs.com; BofA Securities, Inc., Attention:
Prospectus Department, 200 North College Street, 3rd floor,
Charlotte NC 28255-0001 or by email at
dg.prospectus_requests@bofa.com; SVB Securities LLC, Attention:
Syndicate Department, 53 State Street, 40th Floor, Boston, MA
02109, by telephone at 1-800-808-7525, ext. 6105, or by email at
syndicate@svbsecurities.com; or Evercore Group L.L.C., Attention:
Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York,
New York 10055, by telephone at 1-888-474-0200, or by email at
ecm.prospectus@evercore.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc. is committed to supporting and
creating more moments for the neurodegenerative community through
the discovery and development of innovative new treatments. Amylyx
is headquartered in Cambridge, Massachusetts and has operations in
Canada and EMEA.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221011005927/en/
Media
Becky Gohsler Finn Partners (646) 307-6307
amylyxmediateam@amylyx.com
Investors
Lindsey Allen Amylyx Pharmaceuticals, Inc. (857) 320-6244
Investors@amylyx.com
Amylyx Pharmaceuticals (NASDAQ:AMLX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amylyx Pharmaceuticals (NASDAQ:AMLX)
Historical Stock Chart
From Apr 2023 to Apr 2024